Premium
Fibronectin concentration in plasma of patients with breast cancer, colon cancer, and acute leukemia
Author(s) -
Choate Jennifer J.,
Mosher Deane F.
Publication year - 1983
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19830315)51:6<1142::aid-cncr2820510628>3.0.co;2-s
Subject(s) - medicine , breast cancer , fibronectin , chemotherapy , malignancy , sepsis , colorectal cancer , cancer , acute leukemia , leukemia , oncology , gastroenterology , extracellular matrix , biology , microbiology and biotechnology
Abstract Plasma fibronectin was measured in patients with breast cancer, colon cancer, and acute leukemia. In the patients with solid tumors, mean levels were significantly elevated above the mean level of age and sex‐matched normals whether the disease was thought to be metastatic or not ( P < 0.001). It did not make a difference whether the determinations were done prior to or during chemotherapy. Fibronectin was measured serially in eight hospitalized patients with leukemia during intensive induction chemotherapy. Noramal concentrations were found prior to therapy. However, fibronectin concentration fell on the day following chemotherapy in nine of 12 episodes ( P <0.05), and during sepsis in 13 of 13 episodes ( P <0.001). Thus, the concentration was influenced by at least two factors: recent chemotherapy and sepsis. Because fibronectin concentration is sensitive to clinical events other than the status of the malignancy, it seems unsuitable as a tumor marker, at least as a single isolated measurement.